BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10533759)

  • 1. Detection of cancer in augmented breasts by positron emission tomography.
    Noh DY; Yun IJ; Kang HS; Kim YC; Kim JS; Chung JK; Lee DS; Lee MC; Moon WK; Youn YK; Oh SK; Choe KJ
    Eur J Surg; 1999 Sep; 165(9):847-51. PubMed ID: 10533759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours.
    Palmedo H; Bender H; Grünwald F; Mallmann P; Zamora P; Krebs D; Biersack HJ
    Eur J Nucl Med; 1997 Sep; 24(9):1138-45. PubMed ID: 9283107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
    Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
    Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Kuwano H
    Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
    Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
    Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
    Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
    Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
    van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
    Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
    Utech CI; Young CS; Winter PF
    Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
    Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
    Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer.
    Zornoza G; Garcia-Velloso MJ; Sola J; Regueira FM; Pina L; Beorlegui C
    Eur J Surg Oncol; 2004 Feb; 30(1):15-9. PubMed ID: 14736517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Smith IC; Ogston KN; Whitford P; Smith FW; Sharp P; Norton M; Miller ID; Ah-See AK; Heys SD; Jibril JA; Eremin O
    Ann Surg; 1998 Aug; 228(2):220-7. PubMed ID: 9712568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
    Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
    Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
    Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
    Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan.
    Crippa F; Agresti R; Donne VD; Pascali C; Bogni A; Chiesa C; De Sanctis V; Schiavini M; Decise D; Bombardieri E
    Tumori; 1997; 83(2):542-3. PubMed ID: 9226015
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer.
    Barranger E; Grahek D; Antoine M; Montravers F; Talbot JN; Uzan S
    Ann Surg Oncol; 2003 Jul; 10(6):622-7. PubMed ID: 12839846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.